186 related articles for article (PubMed ID: 22157283)
1. Introduction for: frontiers of personalized cancer medicine.
Kucherlapati R
Cancer J; 2011; 17(6):403-4. PubMed ID: 22157283
[No Abstract] [Full Text] [Related]
2. Educating for personalized medicine: a perspective from oncology.
Parkinson DR; Ziegler J
Clin Pharmacol Ther; 2009 Jul; 86(1):23-5. PubMed ID: 19536120
[TBL] [Abstract][Full Text] [Related]
3. The conundrum of personalized cancer management, drug development, and economics.
DeNardo GL
Cancer Biother Radiopharm; 2007 Dec; 22(6):719-21. PubMed ID: 18158762
[No Abstract] [Full Text] [Related]
4. Translational medicine promising personalized therapy in oncology.
Zeng YX; Zhang XS; Liu Q
Front Med China; 2010 Dec; 4(4):351-5. PubMed ID: 21107749
[No Abstract] [Full Text] [Related]
5. Personalized cancer medicine.
Marmé D; Hallek M
Onkologie; 2012; 35 Suppl 1():2. PubMed ID: 22286580
[No Abstract] [Full Text] [Related]
6. Role of nanobiotechnology in developing personalized medicine for cancer.
Jain KK
Technol Cancer Res Treat; 2005 Dec; 4(6):645-50. PubMed ID: 16292884
[TBL] [Abstract][Full Text] [Related]
7. Personalized medicine.
Jain KK
Curr Opin Mol Ther; 2002 Dec; 4(6):548-58. PubMed ID: 12596356
[TBL] [Abstract][Full Text] [Related]
8. Personalized medicine prompts push to redesign clinical trials.
Singer E
Nat Med; 2005 May; 11(5):462. PubMed ID: 15875041
[No Abstract] [Full Text] [Related]
9. Biomathematics in the development of personalized medicine in oncology.
Agur Z
Future Oncol; 2006 Feb; 2(1):39-42. PubMed ID: 16556070
[TBL] [Abstract][Full Text] [Related]
10. What really matters in cancer?: Putting people back into the heart of cancer policy.
Purushotham A; Cornwell J; Burton C; Stewart D; Sullivan R
Eur J Cancer; 2013 May; 49(7):1669-72. PubMed ID: 23434310
[TBL] [Abstract][Full Text] [Related]
11. Molecular imaging and personalized medicine: an uncertain future.
Nunn AD
Cancer Biother Radiopharm; 2007 Dec; 22(6):722-39. PubMed ID: 18158763
[TBL] [Abstract][Full Text] [Related]
12. Phase 0 clinical studies in oncology.
Collins JM
Clin Pharmacol Ther; 2009 Feb; 85(2):204-7. PubMed ID: 19109589
[No Abstract] [Full Text] [Related]
13. It is fascinating to see how nowadays more and more knowledge of the molecular biological characteristics of the tumour lead to individualisation with surgery, radiotherapy and systemic treatment for patients with a malignancy. Introduction.
Bartelink H
Eur J Cancer; 2011 Sep; 47 Suppl 3():xxxv. PubMed ID: 21944037
[No Abstract] [Full Text] [Related]
14. [Molecular medicine--personalized medicine. Principles and state-of-the-art].
Blum HE
Dtsch Med Wochenschr; 2005 Jun; 130(25-26):1568-72. PubMed ID: 15965865
[No Abstract] [Full Text] [Related]
15. Comprehensive cancer control in the United States: progress and opportunity.
Given LS; Hohman K; La Porta M; Belle-Isle L; Rochester P
Cancer Causes Control; 2010 Dec; 21(12):1965. PubMed ID: 21058026
[No Abstract] [Full Text] [Related]
16. Point-of-care routine rapid screening: the future of cancer diagnosis?
Bossmann SH; Troyer DL
Expert Rev Mol Diagn; 2013 Mar; 13(2):107-9. PubMed ID: 23477549
[No Abstract] [Full Text] [Related]
17. Systems medicine: a real approach for future personalized oncology?
Roukos DH
Pharmacogenomics; 2010 Mar; 11(3):283-7. PubMed ID: 20235782
[No Abstract] [Full Text] [Related]
18. [Tumor heterogeneity has considerable importance for the oncology practice].
Versicherungsmedizin; 2013 Mar; 65(1):52-3. PubMed ID: 23593823
[No Abstract] [Full Text] [Related]
19. Multiple biomarkers in molecular oncology.
Johann DJ; Veenstra TD
Expert Rev Mol Diagn; 2007 May; 7(3):223-5. PubMed ID: 17489728
[No Abstract] [Full Text] [Related]
20. Personalized medicine and therapeutic decision-making in oncology: a commentary on key environmental issues.
Freeman RA
J Oncol Pharm Pract; 2011 Sep; 17(3):295-7. PubMed ID: 20551112
[No Abstract] [Full Text] [Related]
[Next] [New Search]
